Search Within

Chaitanya Divgi

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (7)
Groups
  1. Department of Medicine (15)
  2. Genitourinary Oncology Service (15)
  3. Molecular Imaging and Therapy Service (15)
  4. Radiology, Department of (15)
  5. Solid Tumor Oncology Division (15)
  6. GSK Faculty (14)

More Groups

People
  1. Steven Larson (14)
  2. Howard Scher (9)
  3. Michael Morris (8)
  4. Neeta Pandit-Taskar (7)
  5. Ronald Finn (7)
  6. Joseph O'Donoghue (6)

More People

Years
  1. 2008 (1)
  2. 2007 (1)
  3. 2006 (1)
  4. 2005 (2)
  5. 2004 (2)
  6. 2003 (2)

More Years

Publications
  1. Journal of Nuclear Medicine (6)
  2. Clinical Cancer Research (3)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (2)
  4. Current Oncology Reports (1)
  5. Current Urology Reports (1)
  6. European Journal of Nuclear Medicine (1)

More Publications

Publishers
  1. Society of Nuclear Medicine (6)
  2. American Association for Cancer Research (5)
  3. Springer (2)
  4. American Society of Clinical Oncology (1)
  5. Springer Verlag (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy
    Journal Article

    Pandit-Taskar, N.; O'Donoghue, J. A.; Morris, M. J.; Wills, E. A.; Schwartz, L. H.; Gonen, M.; Scher, H. I.; Larson, S. M.; Divgi, C. R.
    Journal of Nuclear Medicine (2008)

    Fulltext@MSK | Save
  • Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Divgi, C. R.; Bender, S.; O'Donoghue, J. A.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Slovin, S.; Finn, R.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
    Meeting Abstract

    Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Targeting osseous metastases: Rationale and development of radio-immunotherapy for prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Divgi, C.; Larson, S.; Scher, H. I.
    Current Urology Reports (2005)

    Fulltext@MSK | Save
  • Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
    Journal Article

    Morris, M. J.; Divgi, C. R.; Pandit-Taskar, N.; Batraki, M.; Warren, N.; Nacca, A.; Smith-Jones, P.; Schwartz, L.; Kelly, W. K.; Slovin, S.; more...
    Clinical Cancer Research (2005)

    Fulltext@MSK | Save
  • Targeting osseous metastases: Rationale and development of radio-immunotherapy for prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Divgi, C.; Larson, S.; Scher, H. I.
    Current Oncology Reports (2004)

    Fulltext@MSK | Save
  • Phase I clinical trial with fractionated radioimmunotherapy using (131)I-labeled chimeric G250 in metastatic renal cancer
    Journal Article

    Divgi, C. R.; O'Donoghue, J. A.; Welt, S.; O'Neel, J.; Finn, R.; Motzer, R. J.; Jungbluth, A.; Hoffman, E.; Ritter, G.; Larson, S. M.; more...
    Journal of Nuclear Medicine (2004)

    Fulltext@MSK | Save
  • Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors
    Meeting Abstract

    Morris, M. J.; Divgi, C.; Kelly, W. K.; Slovin, S.; Solit, D.; Shaffer, D.; Halpern, J.; Delacruz, A.; Curley, T.; Nacca, A.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Optimization of biodistribution parameters for radioimmunotherapy: Clinical trial with HuJ591
    Meeting Abstract

    Pandit-Taskar, N.; Morris, M. J.; Batraki, M.; Perez, A.; Nacca, A.; Smith-Jones, P.; Halpern, J.; Finn, R.; Scher, H. I.; Bander, N. H.; more...
    Journal of Nuclear Medicine (2003)

    Fulltext@MSK | Save
  • Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Divgi, C. R.; O'Donoghue, J. A.; McGagh, D. A.; Motzer, R. J.; Anwar, K.; Sheikh, A.; Gonzalez, R. S.; Welt, S.; Old, L. J.; Larson, S. M.
    Journal of Nuclear Medicine (1999)

    Fulltext@MSK | Save